Table 4.

GVHD outcomes

	aGVHD 2-4				aGVHD 3-4
aGVHD variable	n	RR	99% CI	P	n	RR	99% CI	P
Donor group (main effect)
Parous sibling	880	1.00			880	1.00
Male unrelated	1908	1.56	1.31-1.85	<.0001	1908	1.27	0.98-1.64	.016
GVHD prophylaxis				.002				.0002
Tac + MTX	1094	1.00			1094	1.00
Tac + MTX + others	202	1.12	0.65-1.18	.258	202	1.12	0.72-1.74	.502
Tac ± others	480	1.11	0.84-1.28	.632	480	1.11	0.80-1.53	.410
CsA + MTX	583	0.92	0.80-1.23	.960	583	0.92	0.66-1.28	.500
CsA ± others	315	1.75	1.09-1.72	.0001	315	1.75	1.26-2.43	<.0001
Others	112	1.20	0.91-1.86	.062	112	1.20	0.69-2.10	.389
Graft source
BM	578	1.00			–	–	–	–
PB	2213	1.32	1.08-1.61	.0003	–	–	–	–

	All donor/recipient pairs				Male recipients only
cGVHD variable	n	RR	99% CI	P	n	RR	99% CI	P
Donor/recipient pair (main effect)				<.0001
Parous sibling to female	405	1.00
Parous sibling to male	474	1.39	1.09-1.78	.001	474	1.00
Male unrelated to female	799	1.43	1.14-1.80	<.0001
Male unrelated to male	1099	1.52	1.22-1.89	<.0001	1099	1.09	0.90-1.32	.231
Year of transplant				.002				ns
2000-2003	564	1.00
2004-2008	1471	1.06	0.88-1.29	.381
2009-2012	742	0.86	0.70-1.06	.064
Graft source
BM	574	1			327	1.00
PB	2203	1.73	1.43-2.08	<.0001	1246	1.56	1.23-2.08	<.0001

CI, confidence interval; parous sibling, parous sibling donor; PB, peripheral blood; ns, not significant.